These studies underline the importance of a categorization of TP53 mutations; considering that, when taken together, TP53 mutations were not able to reach significant associations with clinical outcome in advanced or early stage NSCLC, even in patients treated with third-generation TKIs [106,111,114,115,117,118,119,120]. Here, TP53 is linked to non-small cell lung carcinoma.